Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,612,087

« Back to Dashboard
Patent 7,612,087 protects AVYCAZ and is included in one NDA.

This patent has fifty patent family members in thirty-nine countries.

Summary for Patent: 7,612,087

Title:Heterocyclic compounds as inhibitors of beta-lactamases
Abstract: This invention discloses and claims methods for inhibiting bacterial .beta.-lactamases and treating bacterial infections by inhibiting bacterial .beta.-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a .beta.-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a .beta.-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. ##STR00001##
Inventor(s): Aszodi; Jozsef (Tucson, AZ), Fromentin; Claude (Paris, FR), Lampilas; Maxime (Saint Cloud, FR), Rowlands; David Alan (Poissy, FR)
Assignee: Novexel (Romainville, FR)
Application Number:10/898,754
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 30th percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cerexa Inc
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYes7,612,087Nov 12, 2026Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,612,087

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France02 00951Jan 28, 2002

International Patent Family for Patent: 7,612,087

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI293071► subscribe
Taiwan200303305► subscribe
Slovenia2279737► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.